Volume 194, number 12: Clinical and Immunologic Risk Factors for Meningococcal C Conjugate Vaccine Failure in the United Kingdom
14th Nov 2006, 01:00 GMT
Background. The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data. Methods. All subjects with laboratory-confirmed meningococcal serogroup C (MenC) disease from January 2000 to December 2003 in England and Wales were followed up. A vaccine failure was defined as a laboratory-confirmed case of MenC disease occurring 10 days after the subject's last scheduled dose of MCC vaccine. Total immunoglobulins, serum bactericidal antibody (SBA) titers, MCC anticapsular antibody levels, and avidity indices (AIs) were measured in acute and convalescent serum samples from subjects with vaccine failure and unvaccinated subjects with MenC disease. Results. Of 465 subjects with confirmed MenC disease identified among those eligible for vaccination, information on vaccination history was obtained for 462 (99.4%); of these, 53 were subjects with vaccine failure. SBA titers in convalescent serum samples and AIs in acute serum samples were significantly higher in subjects with vaccine failure than in unvaccinated subjects, (6.1-fold higher for SBA titers [[FORMULA]] and 3.2-fold higher for AIs [[FORMULA]]). Conclusions. The antibody response in the subjects with vaccine failure was consistent with an anamnestic response, suggesting that MenC disease occurred despite the MCC vaccine priming for immune memory. Persistence of antibodies may be a more appropriate correlate of long-term protection for MCC vaccines than the ability to generate a booster response on exposure.
Volume 194, number 12: Clinical and Immunologic Risk Factors for Meningococcal C Conjugate Vaccine Failure in the United Kingdom related news:
- Volume 194, number 12: Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines — J Infect Dis Latest Issue
- Flu vaccine associated with slight increase in risk of hospitalization for neurological disorder — EurekAlert! - Breaking News
- Seriousness Of Heart Failure In Elderly Gauged By Seven-Point System — Health News from Medical News Today
- Study: Gastric bypass ups kidney stone risk — United Press International - Consumer Health
- Volume 194, number 12: Increase in Serogroup C Meningococcal Disease in Canada Is Associated with Antigenic Changes in the Protein Antigens of the ET-15 Clone of Neisseria meningitidis — J Infect Dis Latest Issue
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138 — J Infect Dis Latest Issue
- Men who avoid certain risk factors in midlife may have longer, healthier life — EurekAlert! - Medicine and Health
- A nurse prepares to administer a flu vaccine in Massachusetts ... — Top Stories Photos - Reuters on Yahoo! News Photos
- Should We Use Anticoagulation for Patients With Chronic Heart Failure? — Medscape Cardiology Headlines
- Depression, not antidepressants, increases mortality risks in heart failure — EurekAlert! - Social and Behavioral Science
Latest news from J Infect Dis Latest Issue:
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
- Volume 194, number 12: Quantification of Viral Inactivation by Photochemical Treatment with Amotosalen and UV A Light, Using a Novel Polymerase Chain Reaction Inhibition Method with Preamplification
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
- Volume 194, number 12: Evaluation of Purified Taenia solium Glycoproteins and Recombinant Antigens in the Serologic Detection of Human and Swine Cysticercosis
- Volume 194, number 12: Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines
- Volume 194, number 12: Is There a Safe Age for Vaccinating Infants with Tetravalent Rhesus-Human Reassortant Rotavirus Vaccine?
- Volume 194, number 12: Reply to Gargiullo et al.
- Volume 194, number 12: Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease?
- Volume 194, number 12: Human Cytolytic T Cell Recognition of Yersinia pestis Virulence Proteins That Target Innate Immune Responses